Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar 19;23(1):8.
doi: 10.1186/s12962-025-00613-z.

Cost-effectiveness of sacituzumab govitecan for hormone receptor-positive human epidermal growth factor receptor 2-negative metastatic breast cancer based on the EVER-132-002 trial in China

Shixian Liu  1   2   3 , Kaixuan Wang  4 , Hao Chen  1   2   3 , Ziming Wan  1   2   3 , Lei Dou  1   2   3 , Shunping Li  5   6   7
Affiliations

Cost-effectiveness of sacituzumab govitecan for hormone receptor-positive human epidermal growth factor receptor 2-negative metastatic breast cancer based on the EVER-132-002 trial in China

Shixian Liu et al. Cost Eff Resour Alloc. .

Abstract

Background: The EVER-132-002 trial demonstrated the significant efficacy and manageable safety of sacituzumab govitecan in hormone receptor-positive human epidermal growth factor receptor 2-negative (HR + HER2-) metastatic breast cancer. This study evaluated the cost-effectiveness of sacituzumab govitecan compared with chemotherapy from the Chinese healthcare system perspective.

Methods: A partitioned survival model at 21-day intervals over a 10-year time horizon was developed to evaluate the total cost, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratio (ICER) at willingness-to-pay (WTP) threshold of 3 times gross domestic product per capita ($38,042.49 per QALY). Clinical data were extracted from the EVER-132-002 trial; direct medical costs and utility values were obtained from public bid-winning databases, local charges or published literature. To determine the model's robustness, scenario, one-way, two-way and probabilistic sensitivity analyses were performed.

Results: Compared with chemotherapy, sacituzumab govitecan generated an additional cost of $91,273.72, with an additional QALY of 0.43, resulted in an ICER of $211,948.62 per QALY. Patient weight was the most influential parameter on base-case results, and variations in each parameter did not substantially alter the conclusion. Probabilistic sensitivity analysis demonstrated that the probability of sacituzumab govitecan to be cost-effective was zero at the WTP threshold of $38,042.49 per QALY. Scenario analysis indicated that sacituzumab govitecan would be cost-effective versus chemotherapy only if its cost was reduced by 83% ($202.65 per unit) or more.

Conclusions: Sacituzumab govitecan might not be cost-effective compared with chemotherapy in the treatment for HR + HER2- metastatic breast cancer in China.

Keywords: Cost-effectiveness; Hormone receptor-positive; Human epidermal growth factor receptor 2-negative; Metastatic breast cancer; Sacituzumab Govitecan.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: Not applicable. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
The structure of the partitioned survival model
Fig. 2
Fig. 2
The one-way sensitivity analyses of sacituzumab govitecan compared to chemotherapy in China. (Note: PD, progressive disease; PFS, progression-free survival; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year)
Fig. 3
Fig. 3
The incremental cost-effectiveness scatter plot of sacituzumab govitecan compared to chemotherapy in China. (Note: PD, progressive disease; PFS, progression-free survival; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year)
Fig. 4
Fig. 4
The cost-effectiveness acceptability curve of sacituzumab govitecan compared to chemotherapy in China. (Note: WTP, willingness to pay; QALY, quality-adjusted life-year)
See this image and copyright information in PMC

References

    1. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229–63. - PubMed
    1. Han B, Zheng R, Zeng H, Wang S, Sun K, Chen R, Li L, Wei W, He J. Cancer incidence and mortality in China, 2022. J Natl Cancer Cent. 2024;4:47–53. - PMC - PubMed
    1. Gao HF, Lin YY, Zhu T, Ji F, Zhang LL, Yang CQ, Yang M, Li JQ, Cheng MY, Wang K. Adjuvant CDK4/6 inhibitors combined with endocrine therapy in HR-positive, HER2-negative early breast cancer: A meta-analysis of randomized clinical trials. Breast. 2021;59:165–75. - PMC - PubMed
    1. Si W, Li Y, Han Y, Zhang F, Wang Y, Li Y, Linghu RX, Zhang X, Yang J. Epidemiological and clinicopathological trends of breast Cancer in Chinese patients during 1993 to 2013: A retrospective study. Med (Baltim). 2015;94:e820. - PMC - PubMed
    1. Shao H, Zhao M, Guan AJ, Shao T, Zhou D, Yu G, Tang W. A network meta-analysis of efficacy and safety for first-line and second/further-line therapies in postmenopausal women with hormone receptor-positive, HER2-negative, advanced breast cancer. BMC Med. 2024;22:13. - PMC - PubMed

LinkOut - more resources